Novel M-component based biomarkers in Waldenström's macroglobulinemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 1, 2011, Pages 164-167

  Leleu, Xavier ^a   Koulieris, Efstathios ^b   Maltezas, Dimitrios ^b   Itzykson, Raphael ^d   Xie, Wanling ^c   Manier, Salomon ^a   Dulery, Remy ^a   Boyle, Eilleen ^a   Gauthier, Jordan ^a   Poulain, Stéphanie ^a   Tatiana, Tzenou ^b   Panayiotidis, Panayiotis ^b   Bradwell, Arthur R ^e   Harding, Stephen ^f   Leblond, Veronique ^d   Kyrtsonis, Marie Christine ^b   Ghobrial, Irene M ^c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b LAIKO GENERAL HOSPITAL   (Greece)

^c HARVARD MEDICAL SCHOOL   (United States)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^f Binding Site Group Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN M;

B CELL LYMPHOMA; CONFERENCE PAPER; DISEASE COURSE; DISEASE MARKER; HUMAN; IMMUNOASSAY; QUANTITATIVE ASSAY; SENSITIVITY ANALYSIS; SERUM FREE LIGHT CHAIN ASSAY; SERUM HEVYLITE IMMUNOASSAY; TUMOR VOLUME; WALDENSTROEM MACROGLOBULINEMIA;

EID: 79953712927     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2011.n.039     Document Type: Conference Paper

References (13)

1. Bradwell AR, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47:673-80. (Pubitemid 32275810)
2. Mead GP, et al. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126:348-54. (Pubitemid 39005714)
3. Dispenzieri A, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23:215-24.
4. Bradwell A, et al. Serum free-light chain analysis (plus hevylite).ed. T.B.S. Ltd. 2010; Birmingham, UK; 304-5.
5. Keren DF, Heavy/Light-chain analysis of monoclonal gammopathies. Clin Chem 2009; 55:1606-8.
6. Fourrier NJ, et al. Nephelometric immunoassay measurements of IgMκ and IgMλ for the assessment of patients with IgM monoclonal gammopathies. (abs. 120a).Clin Chem 2010; 56.
7. Leleu X, et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma 2008; 49:1104-7. (Pubitemid 351943256)
8. Leleu X, et al. The role of serum immunoglobulin free light chain in response and progression in Waldenstrom Macroglobulinemia. Blood 2010; 116: (abstract 3095).
9. Kyrtsonis M, et al. Serum free-light chains in Waldenstrom's macroglobulinemia (WM) patient at diagnosis. Haematologica 2008; 93:418 (abstract 1057).
10. Itzykson R, et al. Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom's macroglobulinemia. Haematologica 2008; 93:793-4. (Pubitemid 351669328)
11. Maltezas D, et al. Clinical Impact of Increased Serum Free Light Chains (sFLCs) or their Ratio (FLCR) in WM at diagnosis and during disease course. Proceeding of the 6th International Workshop on Waldenstrom's macroglobulinemia. Venice 6-10/10/2010; 105.
12. Manier S, et al. IgM Hevylite® accurately measured serum IgM M-spike level in Waldenstrom macroglobulinemia. Blood 2010 (personal data, unpublished).
13. Koulieris E, et al. Quantification of serum IgMκ and IgMλ in patients with Waldenstrom's macroglobulinemia (WM) at diagnosis and during disease course; clinical correlations. Blood 2010; 116: (abstract 3004).